Pasar al contenido principal

NUEVAS TERAPIAS ANTIVIRALES E INMUNOMODULADORAS FRENTE AL SARS-COV-2

PRE2021-099271

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprograma Subprograma Estatal de Formación
Convocatoria Contratos Predoctorales
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA INSTITUT DE RECERCA SOBRE IMMUNOPATOLOGIES-CAIXA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m 6 A protein synthesis routes

  • Molina Molina, Elisa
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Franco-Trepat, Eloi
  • Jarne, Ignasi
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Badia, Roger|||0000-0003-3982-7577
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Revilla, Lluís
  • Franco Cirera, Sandra|||0000-0003-4126-2202
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Roca, Núria
  • Ceada, Gerardo|||0000-0002-0524-4018
  • Kochanowski, Karl|||0000-0002-1884-7694
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Boreika, Rytis|||0000-0001-6720-1577
  • Bordoy, Antoni E.|||0000-0002-1165-542X
  • Soler, Laia|||0009-0000-4122-5079
  • Guil, Sonia|||0000-0002-2257-3331
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
  • Martinez, Miguel Angel|||0000-0002-6681-4950
  • Paredes, Roger|||0000-0002-6553-691X
  • Losada, Alejandro
  • Avilés, Pablo
  • Cuevas, Carmen
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ballana, Ester|||0000-0002-5215-7363
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
Plitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability. In response to plitidepsin, cells upregulate EIF2AK3 and proteins that reduce translation, but also proteins that support proteostasis via ribosome synthesis and cap-independent translation by eIF4G2 and IGF2BP2. While plitidepsin inhibits cap- or internal ribosome entry sites (IRES)-mediated translation, its impact on N6-methyladenosine (m 6 A) translation is limited. In agreement, plitidepsin blocks members of Coronaviridae, Flaviviridae, Pneumoviridae and Herpesviridae families. Yet, it fails to inhibit retroviruses that exploit m 6 A synthesis routes and are blocked by drugs targeting IGF2BP2 m 6 A reader. By deciphering the molecular fingerprint of cells treated with therapies targeting translation we identify a rational approach to select broad-spectrum antivirals with potential to counteract future pandemic viruses. By deciphering the molecular fingerprint of cells treated with host-directed therapies targeting protein translation, the authors identified a rational approach to select for broad-spectrum antivirals with potential to counteract future pandemic viruses.